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Abstract
Background Diverging approaches towards market entry and uptake of biosimilars, even within a country, leads to regional variation 
in biosimilar use. This is the case in Sweden, where the 21 county councils control the healthcare budget and offer regional guidance.
Objectives This study aimed to analyse the market dynamics of originator and biosimilar etanercept (outpatient setting) in the 
different counties of Sweden, and examine the influence of local policy measures and practices, in addition to national policy.
Methods This study was performed in three steps: (1) a structured review of the literature on (biosimilar) policies in Sweden; 
(2) analysis of market data on the counties’ originator and biosimilar etanercept uptake (quarter two 2012 to quarter four 2017) 
provided by IQVIA™; and (3) discussion of findings in face-to-face semi-structured interviews with the national pricing and reim-
bursement agency, key experts in the county councils of Skåne, Västra Götaland and Stockholm, and an industry representative.
Results Notwithstanding the existence of a national managed entry agreement for etanercept, wide variations in biosimilar 
market shares between counties were observed (40–82% in 2017). Over time, early and late adopters of biosimilar etanercept 
can be distinguished. In quarter four 2017, biosimilar market shares of all counties slightly decreased in accordance with the 
lower priced originator product from 1 October 2017. As prescriptions for treatment with etanercept are often provided for 
a year, two approaches are possible to switch patients: active pullback of prescriptions resulting in additional workload, or 
wait until the patient’s next visit. Qualitative analysis indicated that the choice to use the biosimilar or the originator product 
depends on differences in rebated prices of the biosimilar and originator product, the presence of key opinion leaders, local 
guidelines, and financial streams and local gainsharing arrangements. Our estimates of current rebated prices and costs after 
gainsharing for the county councils and Government reveal only limited price differences between products.
Conclusions Regional variations in use of biosimilar etanercept can be seen although prices are coordinated nationally. This 
suggests that counties react differently to price differences and highlights the role of local policy and attitudes of stakehold-
ers towards biosimilars and switching. It seems that some counties are hesitant to switch patients, as it is associated with 
an increased administrative workload that might not be compensated for by savings associated with a lower priced product.
Arnold G. Vulto and Isabelle Huys are the joint last author.
 * Arnold G. Vulto 
 a.vulto@gmail.com
 Evelien Moorkens 
 evelien.moorkens@kuleuven.be
1 Department of Pharmaceutical and Pharmacological 
Sciences, KU Leuven, Leuven, Belgium
2 IQVIA, Solna, Sweden
3 Hospital Pharmacy, Erasmus University Medical Center, 
Rotterdam, The Netherlands
Key Points 
Biosimilar etanercept market shares between Swedish 
counties ranged from 40% to 82% in 2017 even though 
prices are coordinated nationally.
The choice to use the biosimilar or the originator product 
depends on the extent of the rebated price difference, 
the attitude of key opinion leaders, local guidelines, and 
gainsharing arrangements.
Price differences between etanercept products seem to 
be limited and might not compensate for the increased 
workload of switching.
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1 Introduction
Worth US$39.8 billion in global sales in 2017 [1], inhibitors 
of tumour necrosis factor (TNF)-α, a cytokine involved in 
the body’s inflammatory response [2], represent a growing 
share of the global pharmaceutical market and put increasing 
pressure on national healthcare budgets. This market includes 
five different molecules—infliximab, etanercept, adalimumab, 
certolizumab pegol and golimumab—used in treatment of 
rheumatoid arthritis, psoriatic arthritis, ankylosing spondyli-
tis, psoriasis and/or inflammatory bowel disease [3].
Expiration of patents and other exclusivity rights on mol-
ecules in this class allow for competition from biosimilars 
on the market, which might result in lowered treatment costs 
and increased patient access to treatment. Changes in market 
dynamics of products in disease areas using TNF-α inhibi-
tors are expected [4].
Biosimilar infliximab was the first biosimilar of a TNF-α 
inhibitor that received marketing authorisation across 
Europe in 2013, under the names  Inflectra® and  Remsima® 
[5]. Since then the infliximab biosimilars  Flixabi® and 
 Zessly®, and etanercept biosimilars  Benepali® and  Erelzi® 
have also entered the European market. Recently, TNF-α 
inhibitors  Amgevita®/Solymbic®,  Imraldi®,  Cyltezo®, 
 Halimatoz®/Hefiya® and  Hulio® (adalimumab biosimilars) 
gained marketing authorization. Market entry of these prod-
ucts is expected as market exclusivity rights of the originator 
product,  Humira®, expired in October 2018.
In the European Union, decisions on pricing and reim-
bursement and policies on entry and use of medicines are the 
responsibility of the Member States. This results in diverg-
ing approaches towards market entry and uptake of bio-
similars, leading to variations in use of biosimilars between 
countries [4], and even within a country [6–11]. This is the 
case for the different counties of Sweden, implying that the 
decisions of the 21 county councils of Sweden play a role 
in market access of biosimilars, alongside policy measures 
and incentives provided at the national level.
Sweden’s Health and Medical Services Act [12, 13] states 
the responsibilities of the different counties in the provi-
sion of healthcare to the population. Legislation and general 
health policy objectives are determined at the national level, 
but the 21 individual county councils will enforce policy 
measures, provide regional guidance and education on the 
rational use of medicines, and are also responsible to man-
age the healthcare budget for their county [14]. Financing 
of the healthcare system occurs via taxes levied at national 
and county level and patient co-payment (with an annual 
threshold of 2200 Swedish kronor [SEK; ~ €214] for subsi-
dised prescription medicines) [14].
The Dental and Pharmaceutical Benefits Agency, a 
governmental agency under The Ministry of Health and 
Social Affairs, is responsible for decisions on pricing and 
reimbursement of medicines used in the outpatient setting 
(e.g. etanercept) [15]. This means that reimbursed outpa-
tient medicines will have the same price in each county, 
in contrast to the hospital setting, where procurement and 
accompanying pricing agreements occur at the county level. 
For subcutaneous TNF-α inhibitors, a financial-based man-
aged entry agreement exists between the county councils 
and the pharmaceutical companies, led by the Dental and 
Pharmaceutical Benefits Agency (three-party negotiation) 
[7]. Etanercept has been included in these agreements since 
1 April 2016. During the first and the second agreement, 
from April 2016 to September 2016 and from October 2016 
to September 2017, biosimilar etanercept,  Benepali®, was 
ranked as the least expensive product. In the third man-
aged entry agreement, the originator product,  Enbrel®, was 
assigned the least expensive product in a 2-year agreement 
(October 2017 to September 2019). The Dental and Phar-
maceutical Benefits Agency and the Swedish Association 
of Local Authorities and Regions then distribute a list of 
confidential prices to the payers (Drug and Therapeutics 
Committees of the county councils), who can make recom-
mendations. The prescribing physicians will only know a 
price ranking of products included in the managed entry 
agreement. As rebates of these agreements are not transpar-
ent (only a ranking of products is available), list prices are 
not affected, but nonetheless savings can be generated [16]. 
These savings are shared between the Government (40%), 
which has provided a grant for subsidised medicines to the 
counties, and the counties (60%), which promote the use of 
the most cost-effective treatment option.
The aim of this article, the second part in a study on mar-
ket dynamics of biosimilar and originator TNF-α inhibitors 
in Sweden, is to analyse market dynamics of originator and 
biosimilar etanercept in the different counties of Sweden, and 
examine the influence of local policy measures and practices, 
in addition to national policy. The first article discusses market 
dynamics of infliximab, a product mainly used in the hospital 
setting [17], while the focus of this second article is on etaner-
cept, a product used in the outpatient setting (prescriptions 
are issued by specialists in the hospital or private practices, 
and dispensing occurs via the public pharmacy). In contrast 
to infliximab, prices for etanercept are coordinated nation-
ally in Sweden. Still, regional variations in use of etanercept 
are observed, suggesting this is an interesting setting to study 
determining factors other than price in market dynamics.
2  Methods
The methodology of this study follows the same strategy as 
the first article on market dynamics of infliximab [17]: (1) a 
structured review of the literature on (biosimilar) policies in 
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Sweden and its counties; (2) analysis of market data on the 
counties’ originator and biosimilar etanercept market shares; 
and (3) discussion of findings via follow-up interviews with 
key experts in a selection of counties. More details can 
be found in the first paper, as only a summary is provided 
here. As rebates offered in the managed entry agreements 
on etanercept were not included in the IQVIA™ data and 
are not transparent for the latest agreement, only a limited 
analysis of etanercept prices, based on publically available 
information, could be performed.
To describe the main characteristics of the Swedish 
national healthcare system and policies on biosimilars rel-
evant to the outpatient setting, literature in PubMed was 
reviewed up to the end of November 2017. Additionally, 
articles and reports known to the authors were included. To 
illustrate and quantify market dynamics in the etanercept 
market, market data from quarter two of 2012 to quarter four 
of 2017 on different pack sizes of originator and biosimilar 
etanercept in each county were provided by IQVIA™ [18]. 
The evolution in volume (measured as defined daily doses) 
of each product, and market shares of the biosimilar as a 
share of the total etanercept market (based on volume) were 
calculated over time for each county. Rebated prices of origi-
nator and biosimilar etanercept in the latest managed entry 
agreement were estimated based on list prices available 
on the website of the national pricing and reimbursement 
agency (the Dental and Pharmaceutical Benefits Agency) 
and an indicative rebate level for etanercept in a conference 
presentation [19, 20]. After an initial discussion with the 
national pricing and reimbursement agency, semi-struc-
tured interviews were conducted with five representatives 
and experts on biosimilar policy in Skåne, Västra Götaland 
and Stockholm. Additionally, an industry representative was 
also interviewed. Afterwards, results were verified with the 
national pricing and reimbursement agency.
3  Results
3.1  Market Data on Etanercept in All Counties
Data on the uptake of the etanercept biosimilar  Benepali® 
show a wide variation in biosimilar market shares (based 
on volume) between the counties, ranging from 40% in 
Västra Götaland to 82% in Södermanland in 2017. As 
prices of outpatient medicines are determined on a national 
level, this variation in uptake of biosimilar etanercept is 
not driven by price differences between counties. Sales 
of  Erelzi® are not seen until quarter four of 2017 and are 
negligible (0.001% of etanercept market).
When observing biosimilar market shares of counties 
over time, early and late adopters of biosimilar etanercept 
can be distinguished (Table 1). At the time of market entry 
of the biosimilar, most counties seemed not to be prepared, 
with the exception of the county of Dalarna that had an 
initial biosimilar etanercept market share of 48% in quar-
ter two of 2016, while biosimilar market shares in other 
counties ranged from 1 to 15%. Over time, consistently 
lower biosimilar market shares can be observed for Västra 
Götaland. In quarter four of 2017, biosimilar market shares 
slightly decreased in all counties in accordance with the 
lower price of the originator product from 1 October 2017. 
Again, Dalarna was prepared to switch back, as the bio-
similar market share drops from 83% in quarter three of 
2017 to 30% in quarter four of 2017.
An overall increase of the volume of etanercept over 
time can be observed. From quarter two of 2012 to quarter 
four of 2017, the volume of etanercept increased by 56%, 
with a steeper slope after the entry of the first biosimilar 
in quarter two of 2016 (Fig. 1). Two potential explanations 
for this trend were identified during the interviews: (1) the 
adoption of a lower threshold for initiating treatment with 
a biological medicine, in particular for molecules with 
lowered treatment costs, leading to more patients that are 
started on a product for which a biosimilar exists; and (2) 
increased dosing for products that are now less expensive. 
In Stockholm, the increase in volume of etanercept has 
not led to a decrease in volume of other TNF-α inhibi-
tors, meaning that patient access to treatment with TNF-α 
inhibitors has increased over time in Stockholm.
A simulation of rebated prices per vial of originator 
and biosimilar etanercept and associated costs for county 
councils and the Government in the latest managed entry 
agreement on subcutaneous TNF-α inhibitors (1 October 
2017 to 30 September 2019) was performed based on list 
prices available on the website of the Dental and Phar-
maceutical Benefits Agency [20], taking into account that 
prices of etanercept have decreased by approximately 65% 
[19] (Table 2). In the latest managed entry agreement, 
the originator product  Enbrel® was the least expensive 
product. However, from 1 October, biosimilar  Erelzi® was 
introduced at a list price of SEK1514 and the list price 
of biosimilar  Benepali® was lowered from SEK2135 to 
SEK1514, now matching the cost that the county coun-
cils would pay for the originator product (assuming no 
additional discounts/rebates), and in this way limiting 
incentives to switch back to the originator product. Inter-
viewees also indicated that the price difference was small. 
In March 2018, the list price of the originator product was 
further decreased, but a 12-pack of  Benepali® was also 
introduced on the Swedish market, which is, according 
to the simulation, the actual least expensive treatment 
option per year and per patient and can be used to ensure 
market share via stable patients. This was confirmed by 
the interviewees.
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3.2  Local Policy Measures and Practices in Selected 
Counties
The selected counties appear to have similar recommenda-
tions on the use of etanercept. In the county of Stockholm, 
the expert council on rheumatic diseases issued its recom-
mendations in April 2016 [21], stating that there are no rel-
evant differences between  Enbrel® and  Benepali®; therefore, 
it is recommended that the most cost-effective alternative is 
chosen. They also recommend a switch for patients who are 
stable and informed. In Skåne, new recommendations were 
drafted in December 2017 following the outcome of the third 
managed entry agreement on subcutaneous TNF-α inhibitors 
[22]. For the current agreement, the use of  Enbrel® as the 
most cost-effective product is recommended. Also, a switch 
from the biosimilar back to the originator product should 
be offered to the patient. In Västra Götaland, the rheuma-
tology therapy group recommends use of the least expen-
sive product when starting a new patient [23], and also state 
that a one-time switch for stable, informed patients can be 
considered.
As prescriptions for treatment with etanercept are 
mostly provided for a year, two approaches are then pos-
sible to switch patients: active pull-back of prescriptions 
Table 1  Market shares of 
biosimilar etanercept over 
time for the different Swedish 
counties
County 2016 Q2 2016 Q3 2016 Q4 2017 Q1 2017 Q2 2017 Q3 2017 Q4 
Blekinge  14% 49% 80% 81% 81% 77% 76% 
Dalarna 48% 71% 82% 83% 82% 83% 30% 
Gävleborg 4% 14% 24% 38% 56% 63% 62% 
Gotland 15% 44% 64% 69% 78% 75% 70% 
Halland 1% 5% 14% 32% 56% 59% 55% 
Jämtland 8% 56% 72% 74% 83% 84% 64% 
Jönköping 9% 36% 58% 72% 86% 88% 76% 
Kalmar 11% 36% 52% 66% 76% 82% 76% 
Kronoberg 4% 12% 20% 33% 60% 70% 68% 
Norrbotten 4% 14% 49% 57% 64% 59% 58% 
Örebro  3% 5% 29% 63% 71% 74% 73% 
Östergötland 15% 33% 53% 65% 67% 75% 65% 
Skåne  7% 15% 24% 44% 61% 72% 66% 
Södermanland 9% 34% 51% 72% 82% 91% 83% 
Stockholm 7% 22% 37% 49% 59% 65% 62% 
Uppsala 6% 21% 36% 50% 56% 59% 52% 
Värmland 8% 27% 68% 77% 79% 81% 77% 
Västerbotten 8% 12% 47% 65% 69% 75% 69% 
Västernorrland 5% 9% 50% 64% 75% 71% 58% 
Västmanland 4% 17% 43% 70% 81% 87% 70% 
Västra Götaland 5% 16% 26% 32% 39% 44% 43% 
Colours gradually change from red to green with increasing biosimilar market shares
Q quarter
Fig. 1  Volume evolution (in 
defined daily doses) of etaner-
cept in Sweden from quarter 
















Volume Enbrel® Volume Benepali® Volume Erelzi® Total volume etanercept
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resulting in an additional workload, or wait until the 
patient has their next visit. The additional workload asso-
ciated with switching, due to having to call in patients 
to the hospital to see the prescribing physician for a new 
prescription, was acknowledged by the county of Stock-
holm. In Skåne, no prescriptions were pulled back when 
the first biosimilar for etanercept entered the market in 
April 2016, instead they waited for the next visit to talk to 
the patient. Also in Skåne, the interviewees mentioned that 
patients accumulate packages of the originator product at 
home and, thus, they continued using the originator prod-
uct after a change of prescription to the biosimilar. Since 
new price agreements in October 2017, new patients start 
on the originator product (the least expensive etanercept 
in a new managed entry agreement). It was decided that 
patients on the biosimilar would not be actively switched 
back to the originator product since the price difference 
is not large enough, but instead patients would be able 
to decide during the next visit. In Västra Götaland, no 
patients were switched from the originator product to the 
biosimilar, which was less expensive at the time of market 
entry, as concerns regarding the safety of switching still 
existed at that time. In line with regional guidance, only 
new patients were started on the biosimilar. This turned 
out to be a fortunate decision, as in October 2017 the origi-
nator product was announced to be the least expensive 
etanercept product in a new 2-year agreement.
Interviewees indicated that awareness exists among 
physicians in Sweden of healthcare budgets being under 
pressure due to the use of biological medicines. The Swed-
ish healthcare system proved to be a system based on 
solidarity, with physicians having an altruistic approach 
towards the rational use of medicines and redistribution of 
savings. As the number of specialists in each area is rela-
tively low, communication between specialists on how to 
approach the entry of biosimilars and adherence to agree-
ments was found to be facilitated. Savings that are gener-
ated by leveraging competition arising from biosimilars 
are used to increase patient access to treatment, not only 
in this but also in other therapeutic areas, e.g. oncology. 
Counties have a focus on sustainability of healthcare budg-
ets and how to use them in a rational, evidence-based way, 
instead of focusing on making savings.
The interviewees identified several drivers that could 
influence the decision to use the originator product or the 
biosimilar. Except for differences between rebated prices of 
the originator product and the biosimilar, the following driv-
ers differ between the counties and can influence the extent 
to which the most cost-effective product is used. First, the 
attitude of key opinion leaders and clinic heads plays an 
important role, as they are often members of a county coun-
cil expert group and are believed to have an opinion based 
on review of the scientific literature. These opinions can 
both positively or negatively affect biosimilar uptake. Sec-
ondly, prescribing guidance to physicians is offered by the 
county councils in the form of recommendations. Follow-up 
on adherence by prescription monitoring further enforces 
this driver. Thirdly, financial streams and local gainsharing 
CC county council, SEK Swedish kronor
a A rebate level of 65% was applied to the list price of the originator product, but no additional rebates/discounts were taken into account for 
 Benepali® and  Erelzi®, although this might not reflect reality
b 60% of savings (rebate) for the CC in gainsharing agreement with the Government
c 40% of savings (rebate) for the Government in gainsharing agreement with the CCs
Product List price per 
vial (SEK)a






CCb Governmentc CC Government
Current situation (as of 1 March 2018)
 Enbrel® (50 mg, 4 vials) 1899 1540 (65% of price at start 
of agreement)
359 924 616 975 1283
 Benepali® (50 mg, 4 vials) 1514 0 (0%) 1514 0 0 1514 1514
 Erelzi® (50 mg, 4 vials) 1144 0 (0%) 1144 0 0 1144 1144
 Benepali® (50 mg, 12 vials) 774 0 (0%) 755 0 0 774 774
At time of third managed entry agreement (1 October 2017)
 Enbrel® (50 mg, 4 vials) 2370 1540 (65%) 830 924 616 1446 1754
 Benepali® (50 mg, 4 vials) 1514 0 (0%) 1514 0 0 1514 1514
 Erelzi® (50 mg, 4 vials) 1514 0 (0%) 1514 0 0 1514 1514
Table 2  List prices per vial for originator and biosimilar etanercept, authors’ estimates of rebated prices, and costs for county councils and the 
Government after gainsharing in the third managed entry agreement on subcutaneous tumour necrosis factor-α inhibitors (1 October 2017 to 30 
September 2019) [19, 20]
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arrangements in counties lead to different levels of stake-
holder incentivisation.
For reimbursed outpatient medicines, savings are shared 
between the Government and the counties—in 2018 the 
county councils will repay 40% of the savings to the Gov-
ernment. The remaining savings were said to stay within 
the drug budget in Skåne, Stockholm and Västra Götaland. 
In the long-term, savings made by specialists in the hos-
pitals end up with the county councils. In Skåne, approxi-
mately half of the savings in the hospital stay within the 
departments affected and half can be used in other thera-
peutic areas. In the long-term, the hospital budget may be 
decreased. In Stockholm, large hospitals that prescribe out-
patient drugs have to cover 50% of the costs from their own 
budget, and thus also gain savings on that portion. This is 
an incentive for the hospital management, but the risk exists 
that the hospital or department will receive less money the 
following year. In Västra Götaland, savings would also stay 
within hospital departments in the short-term, but the hos-
pital budget might also be decreased over time.
4  Discussion
This article is the second part in a study on the market 
dynamics of biosimilar and originator TNF-α inhibitors in 
Sweden. The current study describes characteristics of the 
Swedish healthcare system relevant to the outpatient setting 
and the market situation of etanercept, the volume evolu-
tion of originator and biosimilar etanercept, and biosimilar 
market share over time in the different counties of Sweden. 
It further exemplifies approaches towards the entry and use 
of biosimilar etanercept for a selection of counties.
The recommendations of the county councils interviewed 
on the use of etanercept [21–23] indicate that attitudes of the 
relevant expert groups conform to the position statement of 
the Swedish Medical Products Agency. This position state-
ment specifies that the biosimilar and the reference product 
have an equivalent benefit–risk balance, and switching from 
the originator biological to the biosimilar is an option for 
stable, well-informed patients [7, 24].
The current system of managed entry agreements has the 
advantage of providing an incentive to county councils to 
promote the uptake of the least expensive product, albeit 
on a voluntary basis. However, this system lacks transpar-
ency and does not attain full competition given that com-
peting bids are only ranked, and actual bid prices are not 
made public. On the other hand, the managed entry agree-
ments include a clause that prices can be renegotiated every 
6 months in the event a company with a new subcutaneous 
TNF-α inhibitor has applied for reimbursement. This might 
stimulate competition more than the use of tender contracts 
with a longer duration in the hospital setting. However, the 
rules on the managed entry agreements are not as well-
defined as in the strict legal framework on tendering. This 
is illustrated by companies bypassing rebate agreements 
by lowering list prices or introducing new package sizes 
(Table 2). By introducing other package sizes, companies 
can make bids that do not affect European/international 
comparison.
In contrast to the infliximab market, where regional 
variation is primarily driven by price differences due to 
different tender contracts, the prices of etanercept prod-
ucts are the same across Sweden. Therefore, differences in 
the decision to switch to the biosimilar or wait for lower 
rebated prices in future agreements seems to purely be 
affected by the differences in counties’ policy and differ-
ences in attitudes of key opinion leaders and prescribers 
towards biosimilars and switching. It seems that for etaner-
cept, some counties are hesitant to switch patients from 
the originator product to the biosimilar as it is associated 
with administrative work to change prescriptions that are 
often prescribed for a whole year. Furthermore, differences 
between rebated prices might not be as substantial as for 
infliximab and counties cannot individually determine the 
duration of the agreement to adapt to physicians’ attitudes. 
The interviewees taught us that counties are not ready for 
multiple switching from the originator to the biosimilar 
and vice versa, or between biosimilars. In contrast, in the 
hospital setting, where tender contracts are managed at the 
county level, counties have more autonomy to align the 
duration of a contract with policy measures. However, the 
latest managed entry agreement with a duration of 2 years 
might encourage physicians to switch patients to the least 
expensive product. As this is the originator product, one 
would expect that biosimilar market shares will rapidly 
decline. Nevertheless, pricing strategies for the biosimilar, 
as illustrated in Table 2, will influence market dynamics.
After launch of the biosimilar, the uptake of biosimi-
lar etanercept was overall quicker than for infliximab 
[7]. This might be because experience had already been 
gained with the infliximab biosimilar in the period before 
the etanercept biosimilar was launched in the Swedish 
market. In addition, in the hospital setting counties could 
be locked into a contract for the originator at the time the 
infliximab biosimilar was launched. A wider variation in 
biosimilar market shares of infliximab than for etanercept 
can be noticed between counties (infliximab: 18–96% 
vs. etanercept: 40–82% in 2017), with biosimilar mar-
ket shares for etanercept not reaching as high values as 
for infliximab, probably due to a limited price difference 
between originator and biosimilar etanercept. There was 
no apparent relation between biosimilar market shares 
of infliximab and etanercept in counties, i.e. a high bio-
similar market share for infliximab does not necessarily 
lead to a high biosimilar market share of etanercept. This 
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might be due to contrasting price differences between the 
originator and biosimilar in a county for infliximab versus 
etanercept.
Overall, it can be noticed that factors influencing deci-
sion-making between biosimilar or originator products 
are considered the same for the infliximab and etanercept 
market, with counties responding to differences in price 
between products. The simulation on actual costs of etaner-
cept in the current managed entry agreement revealed only 
limited differences between the biosimilar and the origi-
nator product, whereas price differences for infliximab in 
the tender system tend to be larger. A limitation of this 
simulation is that rebate estimates were not available for 
the biosimilars, although such rebates may occur in prac-
tice. Another limitation is that the level of market data does 
not discriminate between indications. As these indications 
differ between etanercept and infliximab, i.e. etanercept 
is not prescribed by gastroenterologists, the influence of 
this factor could not be studied. This study on infliximab 
and etanercept highlights the importance of providing pre-
scription guidelines and consultation between stakeholders. 
Future research could aim to investigate pricing and reim-
bursement mechanisms of the outpatient setting in other 
European countries and study whether our observations 
also apply in other markets. Repeating the analysis when 
more competitors have entered the market could also give 
additional insights, as the influence of, for example,  Erelzi® 
could not be examined in this study. In addition, infor-
mation on discounted prices would allow a more in-depth 
insight into market dynamics.
Although the focus of this study was on market dynam-
ics in the biosimilar and originator etanercept market in 
Swedish counties, we surmise that, when looking at future 
market evolutions, the entry of biosimilars to adalimumab 
in October 2018 will influence the current managed entry 
agreement for subcutaneous TNF-α inhibitors. However, 
the current managed entry agreement at the time of writing 
ran until 1 October 2018, while biosimilars for adalimumab 
could only enter the market on 16 October. It was not clear 
from our study how this discrepancy will be approached. 
As prices are negotiated on a national level, it is difficult 
for counties to prepare for changes in prices. In our opin-
ion, and based on learnings from the etanercept market in 
Sweden, three scenarios may occur: (1) the originator is the 
least expensive product and nothing will change; (2) the bio-
similar is the least expensive product, but only new patients 
will start with the biosimilar since the price difference is not 
large enough to incentivise physicians to switch patients; or 
(3) the price difference between the biosimilar and the origi-
nator is large enough that patients will probably be switched 
to the biosimilar. To trigger a second switch, the next bio-
similar should be priced substantially lower.
5  Conclusion
Regional variations in use of biosimilar etanercept can be 
observed although prices are coordinated nationally, indicat-
ing that counties react differently to price differences and 
that the decision to switch or wait for lower prices is only 
affected by the county’s policy and attitudes of key opinion 
leaders and prescribers towards biosimilars and switching. It 
seems that some counties are hesitant to switch patients, as it 
is associated with an increased administrative workload that 
might not be compensated for by savings associated with a 
lower priced product.
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